Fig. 5: Bridging efficacy study with LukAB CC8Δ10C and LukAB RARPR-33 in the deep, mid and top muscle, skin and the spleen in the minipig SSI model. | npj Vaccines

Fig. 5: Bridging efficacy study with LukAB CC8Δ10C and LukAB RARPR-33 in the deep, mid and top muscle, skin and the spleen in the minipig SSI model.

From: A SpA+LukAB vaccine targeting Staphylococcus aureus evasion factors restricts infection in two minipig infection models

Fig. 5

Göttingen minipigs (n = 3/group) were immunized with 100 µg LukAB CC8Δ10C or 100 µg LukAB RARPR-33, both adjuvanted with 250 µL AS01B (25 µg MPL and 25 µg QS 21). The control group received only adjuvant. At 21 days post the third immunization, animals were challenged with 106 CFU S. aureus CC398 in the SSI model. Eight days post challenge, the bacterial burden (log10 CFU per g of tissue) was determined at the surgical site and in the spleen. Each point represents a single animal. Open symbols indicate censored values that are at the limit of detection of the plate reader. The mean of each group is indicated. Statistical significance was determined using Tobit model with Bonferroni post hoc test to correct for multiple comparisons; *P < 0.05. AS01B Adjuvant System AS01B, CC clonal complex, LukAB leukocidin AB, SpA Staphylococcal protein A.

Back to article page